Finance

Lists
Why is EVH down 4.46%?
Dive Deeper
EVH:NYSE
Evolent Health Inc
$3.96
-4.46%
(-0.18) 1D
$3.96
0.00% (0.00)
After hours
Closed: Oct 8, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EVH...
Open
$4.10
High
$4.12
Low
$3.84
Mkt. cap
447.71M
Avg. vol.
2.32M
Volume
2.88M
52-wk high
$8.33
52-wk low
$2.10
EPS
-$4.57
Beta
1.02
Shares outstanding
113.06M
No. of employees
4K
Open
$4.10
High
$4.12
Low
$3.84
Mkt. cap
447.71M
Avg. vol.
2.32M
Volume
2.88M
52-wk high
$8.33
52-wk low
$2.10
EPS
-$4.57
Beta
1.02
Shares outstanding
113.06M
No. of employees
4K
News stories
From web sources and news partners
About Evolent Health Inc
CEO-
Employees4.2K
Founded2011
Headquarters-
SectorHealth care
Websiteevolent.com
Analyst ratings
Based on 12 analysts giving stock ratings to EVH in the past 3 months
Strong buy
Buy
9
Hold
3
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for EVH in the last 3 months.
Highest
Current $3.96
$8.00 (+102.02%)
Average
$5.80 (+46.46%)
Lowest
$3.00 (-24.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ryan Halsted
RBC Capital
Hold
Maintained
$3.00
-24.2%
10/06/2026
John Stansel
J.P. Morgan
Buy
Reiterated
$6.00
+51.5%
08/18/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
$6.00
+51.5%
08/17/2026
Jailendra Singh
Truist Financial
Hold
Reiterated
$6.00
+51.5%
08/12/2026
Daniel Grosslight
Citi
Buy
Upgraded
$6.00
+51.5%
08/11/2026
Richard Close
Canaccord Genuity
Buy
Maintained
$6.00
+51.5%
08/10/2026
Matthew Gillmor CFA
KeyBanc
Hold
Maintained
-
-
08/10/2026
Michael Wiederhorn
Oppenheimer
Buy
Reiterated
$6.00
+51.5%
08/07/2026
Sean Dodge
BMO Capital
Buy
Maintained
$6.00
+51.5%
08/06/2026
Matthew Shea
Needham
Buy
Reiterated
$5.00
+26.3%
08/06/2026
Ryan Daniels
William Blair
Buy
Reiterated
-
-
08/06/2026
David Larsen
BTIG
Buy
Reiterated
$8.00
+102%
07/16/2026
Kevin Caliendo
UBS
Buy
Reiterated
$5.00
+26.3%
05/08/2026
Jeffrey Garro
Stephens
Buy
Maintained
$7.00
+76.8%
02/25/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
$0.02 / -$0.02
+229.87%beat
Revenue / Est. (USD)
652.52M / 599.79M
+8.79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
479.53M
468.72M
496.25M
652.52M
Cost of goods sold
379.76M
371.47M
412.47M
571.68M
Cost of revenue
379.76M
371.47M
412.47M
571.68M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
75.50M
61.86M
72.36M
67.99M
Operating expense
99.12M
106.89M
93.91M
89.55M
Total operating expenses
478.88M
478.36M
506.38M
661.24M
Operating income
658.00K
-9.64M
-10.14M
-8.72M
Other non operating income
80.00K
-552.00K
742.00K
109.00K
EBT including unusual items
-19.96M
-430.81M
-25.72M
-25.65M
EBT excluding unusual items
-14.62M
-28.30M
-25.26M
-24.80M
Income tax expense
906.00K
-1.68M
910.00K
2.72M
Effective tax rate
-4.54%
0.39%
-3.54%
-10.59%
Other operating expenses
-
-
-
-
Net income
-20.86M
-429.13M
-26.63M
-28.36M
Net profit margin
-4.35%
-91.55%
-5.37%
-4.35%
Earnings per share
0.05
-
-0.02
0.02
Interest and investment income
964.00K
868.00K
1.01M
703.00K
Interest expense
-16.48M
-19.01M
-16.87M
-16.86M
Net interest expenses
-15.51M
-18.14M
-15.85M
-16.16M
Depreciation and amortization charges
23.62M
45.04M
21.56M
21.57M
EBITDA
18.67M
29.70M
5.62M
7.05M
Gain or loss from assets sale
-
-14.87M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps